Marginal Zone Lymphoma (MZL) Archives

FDA Investigating Possible Death Risk Linked to TG Therapeutics’ Lymphoma Drug

Clinical Data, Clinical Trials, FDA, Follicular Lymphoma, Lymphoma, Marginal Zone Lymphoma (MZL), PI3K inhibitors, R&D, Therapeutics

The U.S. Food and Drug Administration is investigating a possible death risk for TG Therapeutics’ Ukoniq (umbralisib), which is indicated for two types of lymphoma.

Incyte Withdraws Lymphoma Drug in “Business Decision”

Business, Clinical Trials, FDA, Follicular Lymphoma, Incyte, Lymphomas, Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), New Drug Applications, Product Pipeline, R&D, Solid Tumors

Incyte Corporation withdrew the New Drug Application (NDA) for the company’s candidate drug for various types of lymphoma.

BeiGene’s Brukinsa Wins Accelerated Approval for MZL

Accelerated Approval, B Cells, BeiGene, Business, FDA, Marginal Zone Lymphoma (MZL), New Indications, Shares, Waldenström Macroglobulinemia (WM)

Two weeks after winning U.S. approval as a treatment for adults with Waldenstrom’s macroglobulinemia, BeiGene’s Brukinsa scored again as a treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL).